prevail_prostate_cancer_survival: PREVAIL Model for Prostate Cancer Survival

In cliot: Clinical Indices and Outcomes Tools

PREVAIL Model for Prostate Cancer Survival

Description

Calculates the Prognostic Index for patients with metastatic castration-resistant prostate cancer (mCRPC) based on the PREVAIL trial data (Armstrong et al., 2017). This model predicts overall survival in men treated with enzalutamide or placebo, utilizing 10 baseline clinical and laboratory factors.

Usage

prevail_prostate_cancer_survival(albumin_g_l, alkaline_phosphatase_u_l,
                                 hemoglobin_g_dl, ldh_u_l,
                                 neutrophil_lymphocyte_ratio,
                                 bone_metastases_gt_10, visceral_disease,
                                 pain_score, psa_ng_ml, months_since_diagnosis)

Arguments

albumin_g_l	Numeric. Serum Albumin level in g/L. (Note: Convert from g/dL if necessary by multiplying by 10).
alkaline_phosphatase_u_l	Numeric. Serum Alkaline Phosphatase (ALP) in U/L.
hemoglobin_g_dl	Numeric. Hemoglobin level in g/dL.
ldh_u_l	Numeric. Serum Lactate Dehydrogenase (LDH) in U/L.
neutrophil_lymphocyte_ratio	Numeric. Absolute Neutrophil Count divided by Absolute Lymphocyte Count (NLR).
bone_metastases_gt_10	Numeric (0 or 1). Are there more than 10 bone metastases? (1 = Yes).
visceral_disease	Numeric (0 or 1). Presence of visceral metastases (e.g., liver, lung). (1 = Yes).
pain_score	Numeric. Brief Pain Inventory-Short Form (BPI-SF) Item 3: "Rate your worst pain in the last 24 hours" (0-10).
psa_ng_ml	Numeric. Prostate Specific Antigen level in ng/mL.
months_since_diagnosis	Numeric. Time elapsed since the initial diagnosis of prostate cancer in months.

Value

A list containing:

Prognostic_Index	The calculated linear predictor score.
Risk_Group	General risk categorization based on the prognostic index.

References

Armstrong AJ, Lin P, Tombal B, et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2017;72(6):811-817. doi:10.1016/j.eururo.2017.07.035

Examples

# Example 1: Low Risk Patient
# Alb 42 g/L, ALP 80, Hb 13.5, LDH 180, NLR 2.5, <10 Bone mets,
#No Visceral, Pain 1, PSA 15, 48 months since Dx
prevail_prostate_cancer_survival(42, 80, 13.5, 180, 2.5, 0, 0, 1, 15, 48)

# Example 2: High Risk Patient
# Alb 30 g/L, ALP 300, Hb 10.0, LDH 400, NLR 6.0, >10 Bone mets,
#Visceral Yes, Pain 6, PSA 150, 12 months since Dx
prevail_prostate_cancer_survival(30, 300, 10.0, 400, 6.0, 1, 1, 6, 150, 12)

cliot documentation built on Dec. 1, 2025, 1:06 a.m.